The Lewy Body Dementia Association (LBDA) is proud to present “2025 Research Year in Review: Innovations and Insight” with Dr. David Irwin, MD.
In this webinar, Dr Irwin highlights the most exciting scientific findings of 2025 – explaining how each answers an important question about Lewy body dementia (LBD) or fills a gap in our knowledge, with a focus on both laboratory research and clinical trials. He also offers a glimpse into what researchers expect to learn in 2026.
Find more films from the Lewy Body Dementia Assocation at: https://www.youtube.com/@LBDAtv
10 key takeaways
-
LBD research is accelerating rapidly with a sharp rise in scientific publications.
-
LBD is a multisystem condition with wide variation in symptoms and care needs.
-
Many people with LBD also have mixed pathology including Alzheimer related amyloid and tau changes.
-
New diagnostic tools can now detect alpha synuclein during life using skin biopsy and spinal fluid tests.
-
Biological testing is improving how different subtypes of Lewy body disease are classified.
-
Expanding clinical trials is now the top national research priority for LBD.
-
Early clinical trials in 2025 showed encouraging signals for cognition attention gait and caregiver burden.
-
Blood based biomarkers are showing promise for tracking inflammation neurodegeneration and disease progression.
-
REM sleep behaviour disorder remains one of the strongest early indicators of future LBD.
-
Environmental and systemic factors including air pollution and kidney health may influence Lewy body pathology.
